Gemini Therapeutics, Inc. (NASDAQ:GMTX – Get Free Report) reached a new 52-week high during mid-day trading on Monday . The stock traded as high as $66.89 and last traded at $64.66, with a volume of 245735 shares. The stock had previously closed at $64.82.
Gemini Therapeutics Price Performance
The stock has a 50 day moving average of $55.94 and a two-hundred day moving average of $48.84. The stock has a market capitalization of $2.92 billion, a PE ratio of -67.47 and a beta of -0.12.
About Gemini Therapeutics
Gemini Therapeutics, Inc, a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.
Featured Articles
- Five stocks we like better than Gemini Therapeutics
- Buy P&G Now, Before It Sets A New All-Time High
- The Great CPU Race: AMD and Intel Battle for Dominance
- How to Invest in Biotech Stocks
- GameStop Turns a Profit: So What? It’s Still Not Worth Investing
- What is the Nasdaq? Complete Overview with History
- C3.ai Stock Surges on Strong Sales Despite Profit Concerns
Receive News & Ratings for Gemini Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemini Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
